Merck to buy Prometheus Biosciences for about $11 billion

Merck & Co (MRK.N) said on Sunday it will buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn's disease and building up its presence in immunology. Merck will pay $200 per share for the California-based…#merckco #crohn #merck #robertdavis #pra023 #phaseii #keytruda #acceleron #prometheus #seageninc
Source: Reuters: Health - Category: Consumer Health News Source Type: news